Patents Assigned to Aventis Pharmaceuticals Products Inc.
  • Publication number: 20070101451
    Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.
    Type: Application
    Filed: March 7, 2006
    Publication date: May 3, 2007
    Applicant: Aventis Pharmaceuticals Products Inc.
    Inventors: Michael Jaye, Kim-Anh Doan, John Krawiec, Kevin Lynch, Dilip Amin, Victoria South
  • Publication number: 20060223771
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Application
    Filed: February 15, 2006
    Publication date: October 5, 2006
    Applicant: Aventis Pharmaceuticals Products Inc.
    Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
  • Patent number: 7041497
    Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: May 9, 2006
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
  • Publication number: 20020146829
    Abstract: Processes for making neutral or anionic complexes containing sequestered DNA for gene transfer, by forming a stable colloid containing an aqueous phase having suspended therein a first DNA complex with a cationic surface potential comprising a DNA sequence complexed with a cationic lipid or polymer, and modifying the surface potential of the first DNA complex to form a stable colloid comprising a second DNA complex with a neutral or net anionic surface potential.
    Type: Application
    Filed: November 29, 2001
    Publication date: October 10, 2002
    Applicant: Aventis Pharmaceuticals Products Inc.
    Inventors: Hans Hofland, Donald Lamons, Xiao-Ying Meng
  • Patent number: 6391980
    Abstract: Solid substrates and methods for their preparation are provided, where enhanced functionalization of solid substrates is achieved, so that higher levels of binding of a wide variety of moieties can be obtained. The surface is nitrated with a nitronium agent, where the nitro groups may be modified in a variety of ways to serve as sites for linking. The resulting solid substrates find use in therapy, diagnosis and processing.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 21, 2002
    Assignee: Aventis Pharmaceuticals Products, Inc.
    Inventor: Brian Clark
  • Patent number: 6361936
    Abstract: Solid substrates and methods for their preparation are provided, where enhanced functionalization of solid substrates is achieved, so that higher levels of binding of a wide variety of moieties can be obtained. The surface is nitrated with a nitronium agent, where the nitro groups may be modified in a variety of ways to serve as sites for linking. The resulting solid substrates find use in therapy, diagnosis and processing.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: March 26, 2002
    Assignee: Aventis Pharmaceuticals Products, Inc.
    Inventor: Brian Clark
  • Patent number: 6323227
    Abstract: This invention relates to compounds of formula which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: November 27, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Scott I. Klein, Kevin R. Guertin, Alfred P. Spada, Heinz W. Pauls, Yong Gong, Daniel G. McGarry
  • Patent number: 6306873
    Abstract: This invention relates to compounds of general formula (I): in which Ar is a group selected from: A1, A2, B, C, D, E, Q1-Q3, R1-R9, Z1 and Z2 are as defined in the disclosure, and Y represents carboxy or an acid bioisostere. These compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: October 23, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Christopher J. Burns, Richard Labaudiniere, Stephen Condon, Robert D. Groneberg, Rose M. Mathew, Joseph M. Salvino
  • Patent number: 6307054
    Abstract: The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A wherein R is H, alkyl or aralkyl and phosphoric acid where the ratio of phosphoric acid to water is not less than about 27 to 1 weight %. The invention is also directed to a process for preparing 2,4-dihydroxy-3-nitropyridine comprising reacting 2,4-dihydroxypyridine with nitric acid. The processes of the present invention prepare intermediates which are useful in preparing compounds which are useful for treating cardiovascular disease marked by hypertension or myocardial ischemia, ameliorating ischenic injury or myocardial infarct size, or treating hyperlipidemia or hypercholesterolemia.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: October 23, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Larry K. Truesdale, James P. Sherbine, Benoit J. Vanasse
  • Patent number: 6277865
    Abstract: This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: August 21, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Scott I. Klein, Kevin R. Guertin
  • Patent number: 6274705
    Abstract: The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: August 14, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Scott I. Klein, Bruce F. Molino
  • Patent number: 6258596
    Abstract: The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic therapy.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: July 10, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Patrick Benoit, Eric Bruckert, Patrice Denefle, Nicolas Duverger, Jean-Charles Fruchart, Gérald Luc, Gérard Turpin, Gerd Assmann, Harald Funke
  • Patent number: 6248841
    Abstract: A novel process has been developed for the treatment of crosslinked ethylene-propylene diene monomer (EPDM) elastomer material to decrease its residual peroxide levels. EPDM is used to form the seats and neck gaskets of metering valves used in metered-dose inhalers (MDI). For filled and inverted MDI units these EPDM components are in direct contact with the pharmaceutical formulation media. The process involves exposing the EPDM valve components to a solution of 2-mercaptoethanol, a chemical reducing agent. The 2-mercaptoethanol greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups. EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler. An advantage of this approach is that the treated EPDM would likely retain its favorable physical properties and its good performance in metering valves.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: June 19, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Karl M. Gelotte, Joseph D'Silva
  • Patent number: 6245760
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: June 12, 2001
    Assignee: Aventis Pharmaceuticals Products, Inc
    Inventors: Wei He, Michael R. Myers, Alfred P. Spada
  • Patent number: 6235909
    Abstract: This invention is directed to methods for the preparation of [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[-(3-chloro-2-thienyl)methyl]propyl]amino]-3 H-imidazo[4,5-b]pyridin-3-yl]]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide, methods for the preparation of intermediates thereto, and to said intermediates themselves.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: May 22, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Herve Garcia, Patrick Leon, Benoit J. Vanasse
  • Patent number: 6184382
    Abstract: The invention is directed to improved methods for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: February 6, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Diane C. Salazar, Walter Rodriguez, James P. Sherbine, Rick G. Woodward, Adam W. Sledeski, Matthew R. Powers, Michael K. O'Brien
  • Patent number: 6180632
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: January 30, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire
  • Patent number: 6180759
    Abstract: This invention is directed to a process for preparing a pseudotetrapeptide of formula I or a salt or prodrug thereof wherein is optionally nitrogen protected azaheterocyclyl; is a single or double bond; q is 1-5; B is alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, aralkyl, alkylaryl, or alkylaralkyl; Q2 is H or a carboxylic acid protecting group; J is —H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl; L is OR1, or NR1R2, where R1 and R2 are independently —H, alkyl, cycloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, aralkyl, alkylaryl or alkylaralkyl; and p is 1 or 2 which comprises the coupling of two dipeptides or psuedopeptides.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: January 30, 2001
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: James J. Mencel, Robert Stammler, Christophe Daubie, Michel Lavigne, Benoit J. Vanasse, Robert C. Liu, Patrick Leon, Geoffrey A. D'Netto, Adam W. Sledeski
  • Patent number: 6159978
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: December 12, 2000
    Assignee: Aventis Pharmaceuticals Product, Inc.
    Inventors: Michael R. Myers, Alfred P. Spada, Paul E. Persons, Martin P. Maguire
  • Patent number: RE37850
    Abstract: Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: September 17, 2002
    Assignee: Aventis Pharmaceuticals Products Inc.
    Inventors: Michael C. Jaye, Wilson Burgess, Thomas Maciag, William N. Drohan